Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance (NASDAQ:AUPH)

Core Viewpoint - The article discusses the trading strategies around biotech stocks, particularly focusing on events such as trial results and NDA/BLA approvals, while also covering companies regulated by the FDA [1]. Group 1 - The focus is on trading strategies that capitalize on significant events in the biotech sector [1]. - The article emphasizes the importance of understanding regulatory environments, particularly those governed by the FDA, for investment decisions in biotech [1].